The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Clinical Discovery Awards, 2006Parkinson Disease in the Ohio Amish
Genes play a significant role in the risk of developing Parkinson's disease. Some genes have already been identified, but several others remain to be identified. One way to find these genes is to...
-
Clinical Discovery Awards, 2006Alleviating late motor complications of Parkinson's disease by a continuous dopaminergic treatment with transdermal delivery of L-DOPA Pro-drug
NeuroDerm Ltd. is developing a novel delivery system of levodopa for the treatment of Parkinson's disease. Levodopa, a well-established medication for the treatment of Parkinson's disease (PD), is...
-
Clinical Discovery Awards, 2006The physiological mechanisms and treatment of fatigue in PD - a longitudinal study
Fatigue is a common problem in Parkinson's and many patients continue to be bothered by fatigue despite that they are taking medications to control their motor symptoms. Transcranial magnetic...
-
Target Validation, 2006Identification of therapeutics that protect against toxins and genes implicated in Parkinson’s disease via the Forkhead-mediated transcription pathway
Loss of dopaminergic neurons is one of the cardinal features of Parkinson’s disease. Medications that can delay or prevent dopaminergic loss could be beneficial in treating PD, but the optimal...
-
Community Fast Track, 2005Specific Inhibition of Nucleation of Alpha-synuclein Aggregation as a Therapeutic Strategy
There is considerable evidence that aggregates of the human brain protein alpha-synuclein are a primary cause of the loss of neurons in Parkinson's disease. We have tried to find out what initiates...
-
Community Fast Track, 2005Use of NR2D-selective NMDA Receptor Modulators in the Treatment of PD
The frontline pharmacological treatment for Parkinson’s disease is associated with serious side effects, creating a need for new therapeutic strategies. Recent evidence suggests that selective...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.